NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to ...

TransMedics is revolutionizing organ transplant therapy with its FDA-approved Organ Care System. See why I rate TMDX stock as ...

If you purchased or acquired securities in TransMedics between February 23, 2023 and January 10, 2025 and would like to ...

Beyond analysts' top -and-bottom-line estimates for TransMedics (TMDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the ...

Van ECK Associates Corp grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 102.3% in the fourth ...

NEW YORK, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX ...

The complaint alleges that TransMedics made false and misleading statements, while failing to disclose crucial information. Specifically, the suit contends that TransMedics used kickbacks ...

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...

Tuesday saw Canaccord Genuity reaffirm its Buy rating and $104.00 price target for TransMedics Group (NASDAQ:TMDX) shares, following the release of recent transplant data. The data, provided by the ...

TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ...